Key statistics
As of last trade, Regenxbio Inc (RB0:DEU) traded at 9.25, 19.35% above the 52 week low of 7.75 set on Nov 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.10 |
---|---|
High | 9.50 |
Low | 9.10 |
Bid | 9.10 |
Offer | 9.15 |
Previous close | 9.10 |
Average volume | 641.80 |
---|---|
Shares outstanding | 49.55m |
Free float | 45.88m |
P/E (TTM) | -- |
Market cap | 475.14m USD |
EPS (TTM) | -5.03 USD |
Data delayed at least 15 minutes, as of Nov 25 2024.
More ▼
Press releases
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
- REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
- REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
- REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
- REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
- REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
More ▼